ctDNA and Immunoscore as prognostic markers in stage III colon cancer

Juan Manuel O'Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, explores the prognostic value of circulating tumor DNA (ctDNA) and Immunoscore® in patients with stage III colon cancer from the Phase III IDEA-France (NCT00958737) and HORG (NCT01308066) trials. In both trials, both ctDNA and Immunoscore® were effective as independent prognostic markers, enabling tailored adjuvant treatments for improved patient outcomes. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.